Table 2.

Comparison of trends in renal function in 30 Pima Indian participants with type 2 diabetes and elevated GFR at baselinea

Method of GFR EstimationMean Baseline ValueAnnual Percentage Change ± SDMean Difference ± SDP Valueb
Total cohort (n = 30)
    direct
        iothalamate clearance (ml/min per 1.73 m2)153 ± 27−4.4 ± 10.3%
    indirect
        100/cystatin Cc158 ± 34−4.3 ± 7.4%−0.1 ± 4.0%0.88
        100/creatininec149 ± 37−2.2 ± 8.6%−2.2 ± 5.6%0.09
        Cockroft-Gault (ml/min)167 ± 60−3.4 ± 8.4%−1.0 ± 6.1%0.50
        MDRD (ml/min per 1.73 m2)130 ± 32−2.8 ± 10.3%−1.6 ± 7.9%0.29
Declining renal functiond (n = 20)
    direct
        iothalamate clearance (ml/min per 1.73 m2)156 ± 30−8.1 ± 10.9%
    indirect
        100/cystatin Cc163 ± 34−6.9 ± 7.7%−1.2 ± 4.1%0.21
        100/creatininec148 ± 42−3.8 ± 9.5%−4.3 ± 7.1%0.01
        Cockroft-Gault (ml/min)166 ± 66−4.5 ± 9.5%−3.6 ± 7.5%0.04
        MDRD (ml/min per 1.73 m2)127 ± 35−4.4 ± 11.2%−3.7 ± 7.9%0.07
Stable renal function (n = 10)
    direct
        iothalamate clearance (ml/min per 1.73 m2)148 ± 182.9 ± 2.0%
    indirect
        100/cystatin Cc149 ± 340.8 ± 2.8%2.1 ± 3.0%0.06
        100/creatininec153 ± 251.1 ± 5.3%1.8 ± 5.2%0.29
        Cockroft-Gault (ml/min)171 ± 48−1.4 ± 5.4%4.3 ± 5.1%0.03
        MDRD (ml/min per 1.73 m2)137 ± 210.7 ± 7.1%2.2 ± 6.7%0.30
  • a GFR >120 ml/min per 1.73 m2 as determined by iothalamate clearance standardized for BSA.

  • b Paired t test statistic.

  • c Arbitrary units.

  • d Defined as a negative annual change in GFR as determined by iothalamate clearance standardized for BSA.